This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Synthetic Biologics Initiates Manufacturing Process For C. Difficile Infectious Disease Program

ROCKVILLE, Md., July 18, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today the initiation of the manufacturing process of the Company's proprietary beta-lactamase enzyme (SYN-004) to target the prevention of Clostridium difficile (C. difficile or C. diff) infections. Pursuant to an agreement with FUJIFILM Diosynth Biotechnologies UK Limited (Fujifilm), the initial phase of the SYN-004 manufacturing process is underway with the evaluation of beta-lactamase protein expression in Fujifilm's pAVEway™ platform. SYN-004 will be evaluated for production cell line yields as well as biological activity of the enzyme product.

"Initiating this expression platform evaluation with Fujifilm is an important first step in the SYN-004 manufacturing process. These efforts move us toward our goal of developing a prophylactic to prevent the devastating effects of C. diff infections, for which there is currently no vaccine or other approved preventive therapy," stated Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. "Upon completion of production cell line evaluation and selection of the optimal expression clone, we intend to proceed rapidly with manufacturing of preclinical material for animal studies, and cGMP production of SYN-004 for clinical studies."

Steve Bagshaw, Managing Director of Fujifilm Diosynth Biotechnologies UK Limited said, "We are excited to have the opportunity to demonstrate to Synthetic Biologics the versatility of our pAVEway™ expression system for SYN-004 production."

SYN-004: Targeting the Prevention of C. difficile Infections

In November 2012, Synthetic Biologics, Inc. acquired a series of oral beta-lactamase enzymes (P1A, P2A and P3A) and related assets targeting the prevention of C. difficile infections (CDI), the leading cause of hospital acquired infections (HAI), that generally occur secondary to treatment with intravenous antibiotics. The acquired assets include a pre-Investigational New Drug (IND) package for SYN-004, a 2 nd generation oral enzyme candidate (formerly known as Ipsat Therapeutics P3A); Phase I and Phase II clinical data for P1A (a 1 st generation oral enzyme candidate); manufacturing processes and data; and, a portfolio of issued and pending U.S. and international patents intended to support an IND and Biologic License Application (BLA) with the U.S. Food and Drug Administration.

Utilizing this portfolio of assets, the Company intends to develop a proprietary oral beta-lactamase enzyme product candidate, SYN-004. When co-administered with certain intravenous beta-lactam antibiotics, it is expected that SYN-004 can degrade the antibiotic that is excreted in the gastrointestinal (GI) tract, thus preserving the natural balance of the patient's microflora, and preventing opportunistic infections including CDI. Beta-lactam antibiotics are a mainstay in hospital infection management and include the commonly used penicillin and cephalosporin classes of antibiotics. In 2012, 15 million Americans were administered beta-lactam antibiotics.*

Stock quotes in this article: SYN 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs